Browse Studies — Arctuva

Phase 1

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-…

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+8 more

Estimated

~$10 – $8,750

Radiopharm Theranostics, LtdNCT07189871

Phase 1

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metasta…

NSCLC (Advanced Non-small Cell Lung Cancer)HNSCCCRC (Colorectal Cancer)+4 more

Estimated

~$10 – $8,750

ALX Oncology Inc.NCT07085091

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diag…

Hepatocellular Carcinoma (HCC)CholangiocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)+3 more

Estimated

~$10 – $750

City of Hope Medical CenterNCT07224750